HS-10502 Combination Treatment in Patients With Advanced Solid Tumors

HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.

Trial Details

NCT ID
NCT06769425
Phase
PHASE1
Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • HS-10502 + NHA
  • HS-10502 + HS-20093
  • HS-10502+ Apatinib
  • HS-10502 + HS-20089
  • HS-10502 + Platinum + Bevacizumab
  • HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Males or females aged 18 years or older (≥18 years).
  • Patients diagnosed with pathologically confirmed advanced solid tumors.
  • Subjects have at least one target lesion as assessed per the RECIST 1.1.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 1 and no deterioration within 2 weeks before the first dose.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →